Pharmacodynamic activity of five oral cephalosporins against Haemophilus influenzae

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 235-241

  Stein, Gary E ^a,d   Schooley, Sharon ^a   Walker, Robert D ^b   Strenkoski Nix, Laura ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Center for Comparative Medicine and Translational Research   (United States)

^c Diabetes Center Millard Filmore Hospital   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFACLOR; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; LORACARBEF;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; COMPARTMENT MODEL; DRUG BLOOD LEVEL; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN EXPERIMENT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; RESPIRATORY TRACT INFECTION; STRAIN DIFFERENCE;

ADULT; CEFACLOR; CEFTIZOXIME; CEFUROXIME; CEPHALOSPORINS; CROSS-OVER STUDIES; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; SERUM BACTERICIDAL TEST;

EID: 0030971407     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-25.
2. Smith GH. Oral cephalosporins in perspective. DICP, Ann Pharmacother 1990;24:45-51.
3. Schatz BS, Karavokiros KT, Taeubel MA, Itokazu GS. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Ann Pharmacother 1996;30:258-68.
4. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
5. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995;28:143-60.
6. Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualization with cefmenoxime. Am J Med 1984;77(suppl 6A):43-50.
7. Wolfson JS, Swartz MN. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med 1985;312:968-75.
8. Lemmen SW, Hauer T, Anding K, Engels I, Daschner FD. Serum bactericidal activity against Moraxella catarrhalis and Streptococcus pneumoniae after administration of four oral cephalosporins in healthy volunteers. J Antimicrob Chemother 1995;35:233-5.
9. Lemmen S, Kropec A, Engels I, Busse A, Daschner FD. Serum bactericidal activity after administration of four cephalosporins in healthy volunteers. Eur J Clin Microbiol Infect Dis 1993;12:856-60.
10. Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther 1989;46:674-85.
11. DeSante KA, Zeckel ML. Pharmacokinetic profile of loracarbef. Am J Med 1992;92(suppl 6A):16-19.
12. Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Pittman KA. Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor. Antimicrob Agents Chemother 1990;34:1210-13.
13. Williams PEO, Harding SM. The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J Antimicrob Chemother 1984;13:191-6.
14. Edberg SC. The measurement of antibiotics in human body fluids: techniques and significance. In: Lorian V, ed. Antibiotics in laboratory medicine, 2nd ed. Baltimore: Williams & Wilkins, 1986:381-479.
15. Dabernat H, Avril JL, Boussougant Y. In vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections. J Antimicrob Chemother 1990;26(suppl E):1-6.
16. Bauernfeind A, Jungwirth R. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefatamet, ceftibutin, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection 1991;19:353-62.
17. National Committee for Clinical Laboratory Standards. Methodology for the serum bactericidal test. Villanova, PA: National Committee for Clinical Laboratory Standards, 1992.
18. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
19. Chen RR, Lee TY, Hsieh WC. Effect of food on pharmacokinetics of cefuroxime axetil in Chinese subjects. J Formos Med Assoc 1992;91:1177-81.
20. Lode H, Muller C, Borner K, Nord C, Koeppe P. Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers. Antimicrob Agents Chemother 1992;36: 144-9.
21. Shyu WC, Shah VR, Campbell DA, Wilber RB, Pittman KA, Barbhaiya RH. Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans. J Clin Pharmacol 1992;32:798-803.
22. Lees AS, Andrews JM, Wise R. The pharmacokinetics, tissue penetration and in-vitro activity of loracarbef, a β-lactam antibiotic of the carbacephem class. J Antimicrob Chemother 1993;32:853-9.
23. Therasse DG, Farlow BS, Davidson RL, et al. Effects of renal dysfunction on the pharmacokinetics of loracarbef. Clin Pharmacol Ther 1993;54:311-16.
24. Nicolau DP, Quintiliani R, Nightingale CH. Antibiotic kinetics and dynamics for the clinician. Med Clin North Am 1995;79:477-95.
25. Craig W. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microbiol Infect Dis 1993;12(suppl 1):S6-8.
26. Nishida M, Murakawa T, Kamimura T, Okada N. Bactericidal activity of cephalosporins in an in-vitro model simulating serum levels. Antimicrob Agents Chemother 1978;14:6-12.
27. Vogelman B, Gudmundsson S, Leggett J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
28. Onyeji C, Nicolau DP, Nightingale CH, Quintiliani R. Optimal times above the MICs of ceftibuten and cefaclor in experimental intra-abdominal infections. Antimicrob Agents Chemother 1994;38:1112-17.
29. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988;32:289-97.
30. Stratton CW. Serum bactericidal test. Clin Microbiol Rev 1988;1:19-26.
31. Ginsburg CM, McCracken GH, Petruska M, Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985;28:504-7.
32. Wiedemann B, Jansen A. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model. J Antimicrob Chemother 1990;26:71-9.